ArticleFrontiers in pharmacology2026
A biomarker-guided framework for corticosteroid treatment stratification in acute exacerbation of idiopathic pulmonary fibrosis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute exacerbation of idiopathic pulmonary fibrosis is a fatal acute-on-chronic respiratory event with limited evidence-based treatment options. Systemic corticosteroids remain widely used, yet their benefit in unselected patients is uncertain, and indiscriminate immunosuppression may expose some patients to harm. A major translational gap is that most available biomarkers describe diagnosis, risk, or prognosis, but do not identify whether corticosteroids actually modify patient outcomes. This Hypothesis and Theory article proposes a testable, biomarker-guided conceptual framework that reframes corticosteroid treatment in acute exacerbation of idiopathic pulmonary fibrosis-from the question of average benefit in unselected patients to the hypothesis that corticosteroid effects differ across corticosteroid-responsive, corticosteroid-neutral, and corticosteroid-harm-prone biological states. We synthesise evidence on disease biology, corticosteroid outcome data, and candidate circulating, imaging, microbiological, and physiological biomarkers. Epithelial injury, inflammatory activation, fibroproliferation, endothelial and coagulation injury, infection or other trigger burden, radiological extent, oxygenation, and early clinical trajectory are evaluated as components of a treatment-stratification framework. We emphasise that these markers currently function mainly as diagnostic, risk, prognostic, safety, or dynamic-response markers rather than validated predictors of corticosteroid response. To bridge this gap, we propose a translational framework that integrates baseline biological signals with structured reassessment at 72-96 h. This framework separates three decision domains: inflammatory reversibility (the likelihood of corticosteroid-modifiable sterile inflammation), irreversible epithelial/fibroproliferative injury (the burden of structural damage unlikely to be modified by corticosteroids), and infection- or host vulnerability-related harm risk (the probability that immunosuppression is unsafe). It is intended to guide prospective treatment-aware cohorts, biomarker-by-treatment interaction analyses, target-trial emulation, and biomarker-enriched or adaptive trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.